Patents by Inventor Mary Lou Wratten

Mary Lou Wratten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kit, system and method of treating myeloma patients
    Patent number: 8672869
    Abstract: Circulating free lambda and kappa free light chains in blood play a role in the pathogenesis of acute renal failure due to myeloma. Coupled plasma filtration and adsorption allows separation of plasma from blood and treatment of the plasma through a cartridge containing a sorbent or resin material, such as hydrophobic divinylbenzene styrenic resins having an average bead diameter of 75 microns, an average pore diameter of 30 nm, and a surface area of 700 m2/g. Lambda and kappa free light chain concentrations progressively decrease during coupled plasma filtration and adsorption treatment resulting in significant reductions by the end of the treatment.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 18, 2014
    Assignee: Bellco S.r.l.
    Inventors: Mary Lou Wratten, Mauro Atti, Antonio Santoro
  • Use of Polymeric Resins for the Adsorptive Extracorporeal Removal of Inflammatory Mediators in the Treatment of Systemic Inflammation-Related Diseases
    Publication number: 20120312732
    Abstract: It is described a kit for treating a systemic inflammatory related disease comprising a) a high permeability filter having a pore size designed to let inflammatory mediators to pass and b) means to retain said mediators but not serum albumin.
    Type: Application
    Filed: June 20, 2012
    Publication date: December 13, 2012
    Applicant: BELLCO S.r.l.
    Inventors: Mauro Atti, Mary Lou Wratten
  • KIT, SYSTEM AND METHOD OF TREATING MYELOMA PATIENTS
    Publication number: 20090112146
    Abstract: Circulating free lambda and kappa free light chains in blood play a role in the pathogenesis of acute renal failure due to myeloma. Coupled plasma filtration and adsorption allows separation of plasma from blood and treatment of the plasma through a cartridge containing a sorbent or resin material, such as hydrophobic divinylbenzene styrenic resins having an average bead diameter of 75 microns, an average pore diameter of 30 nm, and a surface area of 700 m2/g. Lambda and kappa free light chain concentrations progressively decrease during coupled plasma filtration and adsorption treatment resulting in significant reductions by the end of the treatment.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 30, 2009
    Applicant: Sorin Group Italia
    Inventors: Mary Lou Wratten, Mauro Atti, Antonio Santoro